These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

384 related articles for article (PubMed ID: 30835007)

  • 1. Evidence-Based Practice: Temozolomide Beyond Glioblastoma.
    Chua J; Nafziger E; Leung D
    Curr Oncol Rep; 2019 Mar; 21(4):30. PubMed ID: 30835007
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article.
    Koukourakis GV; Kouloulias V; Zacharias G; Papadimitriou C; Pantelakos P; Maravelis G; Fotineas A; Beli I; Chaldeopoulos D; Kouvaris J
    Molecules; 2009 Apr; 14(4):1561-77. PubMed ID: 19384285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of initial temozolomide for high-risk low grade gliomas in a phase II AINO (Italian Association for Neuro-Oncology) study: a post-hoc analysis within molecular subgroups of WHO 2016.
    Rudà R; Pellerino A; Pace A; Carapella CM; Dealis C; Caroli M; Faedi M; Bello L; Migliore E; Marchese G; Bertero L; Cassoni P; Soffietti R
    J Neurooncol; 2019 Oct; 145(1):115-123. PubMed ID: 31556015
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prescription guidebook for temozolomide usage in brain tumors].
    Tilleul P; Brignone M; Hassani Y; Taillandier L; Taillibert S; Cartalat-Carel S; Borget I; Chinot O
    Bull Cancer; 2009 May; 96(5):579-89. PubMed ID: 19467988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accelerated hyperfractionated radiochemotherapy with temozolomide is equivalent to normofractionated radiochemotherapy in a retrospective analysis of patients with glioblastoma.
    Lewitzki V; Klement RJ; Kosmala R; Lisowski D; Flentje M; Polat B
    Radiat Oncol; 2019 Dec; 14(1):227. PubMed ID: 31831026
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temozolomide chemotherapy of patients with recurrent anaplastic astrocytomas and glioblastomas.
    Sipos L; Vitanovics D; Afra D
    Ideggyogy Sz; 2004 Nov; 57(11-12):394-9. PubMed ID: 15662767
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Temozolomide and treatment of malignant glioma.
    Friedman HS; Kerby T; Calvert H
    Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is add-on Bevacizumab therapy to Temozolomide and radiotherapy associated with clinical utility for newly diagnosed Glioblastoma? A systematic review and meta-analysis.
    Habibi MA; Shad N; Mirjnani MS; Fasihi S; Sadeghi S; Karami S; Ahmadvand MH; Delbari P; Zare AH; Zare AH; Alavi SAN
    Neurosurg Rev; 2024 Aug; 47(1):445. PubMed ID: 39162874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Concurrent and Adjuvant Temozolomide for Newly Diagnosed Grade III Gliomas without 1p/19q Co-deletion: A Randomized, Open-Label, Phase 2 Study (KNOG-1101 Study).
    Hwang K; Kim TM; Park CK; Chang JH; Jung TY; Kim JH; Nam DH; Kim SH; Yoo H; Hong YK; Kim EY; Lee DE; Joo J; Kim YJ; Choe G; Choi BS; Kang SG; Kim JH; Kim CY
    Cancer Res Treat; 2020 Apr; 52(2):505-515. PubMed ID: 31671938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of Cyclin D1 Expression in Human Glioblastoma Cells is Associated with Increased Temozolomide Chemosensitivity.
    Zhang D; Dai D; Zhou M; Li Z; Wang C; Lu Y; Li Y; Wang J
    Cell Physiol Biochem; 2018; 51(6):2496-2508. PubMed ID: 30562739
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cerebral blood volume and apparent diffusion coefficient - Valuable predictors of non-response to bevacizumab treatment in patients with recurrent glioblastoma.
    Petrova L; Korfiatis P; Petr O; LaChance DH; Parney I; Buckner JC; Erickson BJ
    J Neurol Sci; 2019 Oct; 405():116433. PubMed ID: 31476621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgery, radiotherapy and temozolomide in treating high-grade gliomas.
    Parlato C; Barbarisi M; Moraci M; Moraci A
    Front Biosci; 2006 May; 11():1280-3. PubMed ID: 16368514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term impact of temozolomide on 1p/19q-codeleted low-grade glioma growth kinetics.
    Izquierdo C; Alentorn A; Idbaih A; Simó M; Kaloshi G; Ricard D; Barritault M; Meyronet D; Bruna J; Honnorat J; Delattre JY; Ducray F
    J Neurooncol; 2018 Feb; 136(3):533-539. PubMed ID: 29143276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme.
    Aoki T; Mizutani T; Ishikawa M; Sugiyama K; Hashimoto N
    Int J Clin Oncol; 2003 Oct; 8(5):301-4. PubMed ID: 14586755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Temozolomide and radiation in low-grade and anaplastic gliomas: temoradiation.
    Schiff D
    Cancer Invest; 2007 Dec; 25(8):776-84. PubMed ID: 17952745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan (CPT-11) in children with high-risk malignant brain tumors: the Duke experience.
    Turner CD; Gururangan S; Eastwood J; Bottom K; Watral M; Beason R; McLendon RE; Friedman AH; Tourt-Uhlig S; Miller LL; Friedman HS
    Neuro Oncol; 2002 Apr; 4(2):102-8. PubMed ID: 11916501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temozolomide-induced flare in high-grade gliomas: a new clinical entity.
    Rosenthal MA; Ashley DL; Cher L
    Intern Med J; 2002 Jul; 32(7):346-8. PubMed ID: 12088355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Valproic acid, compared to other antiepileptic drugs, is associated with improved overall and progression-free survival in glioblastoma but worse outcome in grade II/III gliomas treated with temozolomide.
    Redjal N; Reinshagen C; Le A; Walcott BP; McDonnell E; Dietrich J; Nahed BV
    J Neurooncol; 2016 May; 127(3):505-14. PubMed ID: 26830093
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Temozolomide for immunomodulation in the treatment of glioblastoma.
    Karachi A; Dastmalchi F; Mitchell DA; Rahman M
    Neuro Oncol; 2018 Nov; 20(12):1566-1572. PubMed ID: 29733389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.